Prestige Consumer Healthcare just finished the largest brand purchase in its recent history after a year in which its flagship eye drop could not reliably reach the shelf. The company closed the Breathe Right nasal-strip portfolio in mid-June for just over $1 billion and followed with an Australian skin-care tuck-in in early July. Management now treats Breathe Right as the largest brand in the house. That is the event. The equity debate is no longer whether the legacy book can grind out mid-single-digit growth on its own. The debate is whether a debt-funded step-up in scale converts into cash fast enough to bring leverage back down while Clear Eyes remains a supply problem rather than a growth engine.
Organic sales in the June quarter still rose after stripping currency and the partial-period contribution from the new brands. Gastrointestinal names such as Dramamine and Fleet, plus skin care led by Compound W, carried that print. Retailer order timing added about 2 percentage points to growth, a lift management already flags as a second-quarter giveback. GAAP diluted earnings fell to $0.61. That compares with $0.95 a year earlier, because deal costs, inventory step-up, and idle-capacity charges at the Pillar5 sterile plant landed together. Adjusted earnings still rose to $0.98, and adjusted free cash flow set a quarterly record on working-capital timing. The cash engine is intact even as the income statement turns noisier than it has been in years.
Net debt now sits near $2 billion after the term-loan financing. Equity value is only a little above that same $2 billion mark, so the enterprise is now as much a credit story as a brand story. Management raised current-year sales guidance to a band near $1.3 billion entirely for the two purchases and left the organic growth range unchanged. Shares recently changed hands near $45, close to the bottom of the past-year range. The next several quarters decide whether Breathe Right behaves like a bolt-on cash machine and whether Pillar5 output stabilizes in the second half. If either slips, the cheap-looking earnings multiple is cheap for a reason.